Editor’s note: This is a developing news story. Please check back soon for updates.
Cloudbreak Pharma reported positive topline results from a phase 2 clinical trial that assessed a preservative-free ophthalmic solution for the treatment of vascularized pinguecula and associated conjunctival hyperemia.
The study included 88 adults with vascularized pinguecula and conjunctival hyperemia randomly assigned to receive one of two concentrations of CBT-004 or vehicle. The study met its primary endpoint, with both concentrations of CBT-004 significantly improving conjunctival hyperemia at day 28